RxDoctor Payments Data

Nathalie Acher, MD

Family Medicine · Bellevue, WANPI 1801180799

Payments from drug & device makers

$12,184in general payments, 2019–2025

Across 601 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$945
  • Amarin Pharma, Inc.$833
  • Boehringer Ingelheim$752
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$11,97098%
  • Education$2142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,184 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$20,072
Medicare patients
48
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$27,969
OzempicSemaglutide14$21,468
FarxigaDapagliflozin Propanediol16$15,261
EliquisApixaban19$14,774
Atorvastatin Calcium87$735
Gabapentin20$681
Levothyroxine Sodium53$629
Hydrochlorothiazide45$627
Metformin Hcl ErMetformin Hcl38$607
Rosuvastatin Calcium45$587
Bupropion XlBupropion Hcl11$428
Simvastatin24$424
Losartan Potassium30$405
Fluoxetine Hcl29$390
Hydroxyzine Hcl12$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$945$27,96911 claims
Novo NordiskOzempic$1,037$21,46814 claims
AstraZenecaFarxiga$1,284$15,26116 claims
PfizerEliquis$695$14,77419 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$67$16213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →